Sgx Pharmaceuticals, Inc.

Alere San Diego, Inc.

William D Arnold

Mark E Wilson

Ruo W Steensma

Andreas Gosberg

Ian A McDonald

Zhe Li

Pierre Bounaud

Chixu Chen

Stephanie Hopkins

Stefan N Gradl

Brian Walter Eastman

Paul A Sprengeler

Pierre-Yves Bounaud

Masaki Tomimoto

Zhe Li Bounaud

Uday Kumar Veeramallu

Scott Rongey

Jonathan Gary

Joseph Buechler

Kelline Marie Rodems

Christelle Jost

Brian Noland

Scott Harold Rongey

Vance Wong

The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.

Methods and compositions for diagnosis and risk prediction in heart failure

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

Fused ring heterocycle kinase modulators

The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.

Pyrimidinyl-thiophene kinase modulators

The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

Pyrrolo-pyridine kinase modulators

Growing community of inventors

San Diego, CA, United States of America

William D Arnold